Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

Overview of attention for article published in BMC Health Services Research, August 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 2 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 33 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 15,346 followers.

RT @ProfMakris: This study suggests that if the Italian National Health Care system was to switch from standard to extended half life FVIII…

31 Aug 2018

Reply Repost Favourite

This study suggests that if the Italian National Health Care system was to switch from standard to extended half life FVIII, it will be cost saving. A lot depends on the unit prices which are dramatically higher than what we pay in the UK. https://t.co/r0o

31 Aug 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.